<DOC>
	<DOCNO>NCT00936403</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety , tolerability , pharmacokinetics ( determination concentration administer medication blood time ) pharmacodynamics ( determination effect time duration action ) long-acting growth hormone ( NNC126-0083 ) growth hormone deficient child .</brief_summary>
	<brief_title>A Single Dose Trial Growth Hormone Deficient Children Investigating Safety , Pharmacokinetics Pharmacodynamics Long Acting Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Confirmed diagnosis growth hormone insufficiency define two different GH provocation test , define peak GH level le 7ng/ml Prepubertal child Growth hormone replacement treatment least three month Evidence tumour growth malignant disease Growth hormone deficient child overt diabetes mellitus ( fast blood glucose 126mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>